G1 Therapeutics Added to the Russell 2000® and 3000® Indexes
01 juil. 2024 08h00 HE
|
G1 Therapeutics
G1 Therapeutics Added to the Russell 2000® and 3000® Indexes
G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer (mTNBC)
24 juin 2024 06h30 HE
|
G1 Therapeutics
G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negativ
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 juin 2024 07h00 HE
|
G1 Therapeutics
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC)
28 mai 2024 06h30 HE
|
G1 Therapeutics
Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 ADC
G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) Meeting
23 mai 2024 17h06 HE
|
G1 Therapeutics
G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) Meeting
G1 Therapeutics to Participate in TD Cowen’s 5th Annual Oncology Innovation Summit
22 mai 2024 10h00 HE
|
G1 Therapeutics
G1 Therapeutics to Participate in TD Cowen’s 5th Annual Oncology Innovation Summit
G1 Therapeutics and Deimos Biosciences Announce Global (Excluding Asia-Pacific) License Agreement for Lerociclib for Radioprotective Uses
22 mai 2024 06h30 HE
|
G1 Therapeutics
G1 Therapeutics and Deimos Biosciences Announce Global (Excluding Asia-Pacific) License Agreement for Lerociclib for Radioprotective Uses
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 mai 2024 17h50 HE
|
G1 Therapeutics
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights
01 mai 2024 06h30 HE
|
G1 Therapeutics
G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights
G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib
01 mai 2024 06h25 HE
|
G1 Therapeutics
G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib